Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19522520 | 0.82 | MMP1 (0.35) | FFAR2MMP1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL22561303 | 0.82 | MMP1 (0.35) | FFAR2MMP1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL30408938 | 0.82 | MMP1 (0.35) | FFAR2MMP1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL25662649 | 0.82 | MMP1 (0.35) | FFAR2MMP1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL18048546 | 0.78 | MMP2 (0.36) | FFAR2MMP1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL18048547 | 0.78 | MMP2 (0.36) | FFAR2MMP1CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL21335909 | 0.77 | TAS1R3 (0.33) | — | |
| SCHEMBL22267487 | 0.77 | MMP1 (0.39) | MMP1 | |
| SCHEMBL25672807 | 0.75 | ALDH1A1 (0.37) | MMP1 | |
| SCHEMBL25139840 | 0.73 | GAA (0.34) | FFAR2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | BYONDIS B.V. (NL) | 2020-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200297859-A1 | NON-LINEAR SELF-IMMOLATIVE LINKERS AND CONJUGATES THEREOF | DLST, ADSL, LANCL1 | FFAR2 1886/4885MMP1 721/4885CHRNB2 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.